Ken Griffin Vectiv Bio Holding Ag Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

Shares

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2023 Aug 14, 2023	SELL	$8.29 - $16.97 $32.9 Million - $67.3 Million	-3,966,231 Reduced 99.97%	1,306 $22,000
Q1 2023 May 15, 2023	SELL	$7.34 - $9.15 $2,187 - $2,726	-298 Reduced 0.01%	3,967,537 $33.8 Million
Q4 2022 Feb 14, 2023	BUY	$7.79 - $8.98 $6.41 Million - $7.39 Million	822,584 Added 26.15%	3,967,835 $34.4 Million
Q3 2022 Nov 14, 2022	BUY	$4.7 - $6.07 $9,465 - $12,224	2,014 Added 0.06%	3,145,251 $18.9 Million

Others Institutions Holding VECT

# of Institutions

1

Shares Held

510K

Call Options Held

0

Put Options Held

0

Regency Capital Management Inc.\De

510K
Shares

$0
0.0% of portfolio

About VectivBio Holding AG

Ticker VECT
Exchange NASDAQ
Description
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with sho...

More about VECT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.